
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
DALLAS - Mohs micrographic surgery compares favorably with wide excision for treatment of extramammary Pagets disease






